



## Adagio Therapeutics to Participate in Upcoming Investor Conferences

November 10, 2021

WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences:

- **Stifel 2021 Virtual Healthcare Conference:** Management will participate in a fireside chat discussion on Tuesday, November 16, 2021, at 8:40 a.m. ET.
- **Jefferies 2021 Virtual London Healthcare Conference:** Management will participate in a fireside chat discussion during the conference, being held November 16-19, 2021. The fireside chat will be available to registered participants on-demand between 8:00 a.m. GMT on November 18, 2021, and 5:00 p.m. GMT on November 19, 2021.
- **Evercore ISI 4th Annual HealthconX Conference:** Management will participate in a fireside chat discussion on Wednesday, December 1, 2021, at 2:40 p.m. ET.

The webcasts will be available in the investor section of the company's website at [investors.adagiotx.com](https://investors.adagiotx.com) and will be archived for 60 days following the presentations.

### About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company's portfolio of antibodies has been optimized using Adimab's industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio's portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring broad accessibility to people around the world. For more information, please visit [www.adagiotx.com](https://www.adagiotx.com).

### Contacts:

#### Media Contact:

Dan Budwick, 1AB

[Dan@1abmedia.com](mailto:Dan@1abmedia.com)

#### Investor Contact:

Monique Allaire, THRUST Strategic Communications

[monique@thrustsc.com](mailto:monique@thrustsc.com)